BioSpace News Archive

The global market for hepatitis E diagnostic tests is treading a growth path as the prevalence of hepatitis E, especially in resource-poor regions is on the rise.

Tissue injury, also known as soft tissue injury, is an injury of tendons, muscles, and ligaments across the body.

Nanotechnology company BNNano, Inc., biotechnology company Calviri, Inc., and electronics materials company Terecircuits Corporation claimed top recognition on Pepperdine Graziadio Business School’s third annual Most Fundable Companies List, which was announced during the virtual event yesterday.

Arch Biopartners Inc., announced it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Sensient Technologies Corporation reported consolidated revenue of $323.6 million in this year’s third quarter compared to $317.7 million in last year’s third quarter.

Prospective, multi-center study data support use of DecisionDx®-Melanoma in T1-T2 melanoma patients 65 years and older to identify those with a low probability of sentinel lymph node positivity

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, is presenting two abstracts with new data on its first product, the Nu.Q

Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced it will hold its 2020 annual general meeting of shareholders at its Hong Kong office located at 17/F, Guangdong Investment Tower, 148 Connaught Road Central,

Calyxt, Inc., a plant-based technology company, announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 3,750,000 shares of the Company’s common stock, at a purchase price of $4.00 per share, in a registered direct offering.

FORTUNE and Great Place to Work ® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year